Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060843 | 0.83 | NPSR1 (0.44) | NPSR1FLT3ADORA3DYRK1AMIF | |
| SCHEMBL21224373 | 0.77 | CDK8 (0.44) | ADORA3DYRK1ADRD2DRD4DRD3 | |
| SCHEMBL588580 | 0.77 | TLR7 (0.34) | — | |
| SCHEMBL3700731 | 0.75 | ADORA3 (0.47) | NPSR1FLT3ADORA3DYRK1AMIF | |
| SCHEMBL2016621 | 0.75 | NPSR1 (0.46) | NPSR1FLT3ADORA3DYRK1AMIF | |
| SCHEMBL588837 | 0.75 | NPSR1 (0.46) | NPSR1FLT3ADORA3DYRK1AMIF | |
| SCHEMBL14469402 | 0.74 | KDM4E (0.37) | NPSR1NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL31356574 | 0.74 | PIK3CA (0.40) | FLT3PIK3CAGAA | |
| SCHEMBL16898357 | 0.74 | FLT3 (0.39) | FLT3PKMALDH1A1HPGDKDM4E | |
| SCHEMBL9609624 | 0.74 | KDM4E (0.39) | PKMNPC1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368917-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMA INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9278971-B2 | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2014-09-25 | — | — | US | disclosed |
| US-8778942-B2 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778942-B2 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8470851-B2 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470851-B2 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | NPSR1 949/4885FLT3 4693/4885ADORA3 1019/4885 |
| US-20160368917-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | NPSR1 4658/4885FLT3 300/4885ADORA3 4726/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | NPSR1 1351/4885FLT3 4473/4885ADORA3 1672/4885 |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | NPSR1 726/4885FLT3 489/4885ADORA3 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.